AGGRASTAT® Injection Pre-mixed (HCPCS code J3246) is a clear, non-preserved, sterile solution premixed in a vehicle made iso-osmotic with 0.9% sodium chloride.
In 2021, Medicure Pharma reintroduced the AGGRASTAT® 5MG/100ML Bag (NDC: 25208-0002-01). It is the same concentration, ready-to-use- format, storage, and has the same stability properties and price as the AGGRASTAT® 5MG/100ML Vial (NDC: 25208-0002-03). The 5MG/100ML vial format will no longer be manufactured. The 5MG/100ML bag will replace the 5MG/100ML vial.
|Product Format||Product Details|
|15 mL Bolus Vial||25208-0001-04||250 mcg/mL||3.75 mg/15 mL|
|100 mL Bag||25208-0002-01||50 mcg/mL||5 mg/100 mL|
|250 mL Bag||25208-0002-02||50 mcg/mL||12.5 mg/250 mL|
Pre-mixed Bolus Vial
|5 mg/100 ml
|12.5 mg/250 ml
|AmerisourceBergen Drug Corporation||10169784||10261079||10040778|
|Cardinal Health, lnc.||5293881||4073318||4073334|
|Morris & Dickson Company, LLC||856963||930917||859645|
Store AGGRASTAT® at controlled room temperature, 25 °C (77 °F) with excursions permitted between 15–30 °C (59–86 °F). Do not freeze. Protect from light during storage.
Please download our Product Return and Replacement Form or email email@example.com to learn more.
Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
For additional information, refer to the full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA.
or call 1-800-FDA-1088.